- Home
- PALI
PALI
Palisade Bio Inc.
as 07-26-2024 4:00pm EST
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 4.3M | IPO Year: | N/A |
| Target Price: | $22.50 | AVG Volume (30 days): | 71.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -23.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.82 - $34.35 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Palisade Bio Inc. (PALI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Williams Donald Allen | PALI | Director | May 28 '24 | Buy | $4.86 | 1,000 | $4,863.00 | 1,000 | SEC Form 4 |
| Finley John David | PALI | CEO, CFO, Director | May 24 '24 | Buy | $4.81 | 1,000 | $4,810.00 | 8,437 | SEC Form 4 |
| Finley John David | PALI | CEO, CFO, Director | Feb 6 '24 | Buy | $0.47 | 10,000 | $4,692.00 | 84,649 | SEC Form 4 |
| Finley John David | PALI | CEO, CFO, Director | Jan 31 '24 | Buy | $0.56 | 10,000 | $5,590.00 | 74,649 | SEC Form 4 |
| Williams Donald Allen | PALI | Director | Jan 31 '24 | Buy | $0.61 | 10,000 | $6,050.00 | 30,000 | SEC Form 4 |
Latest Palisade Bio Inc. News
PALI Breaking Stock News: Dive into PALI Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108
GlobeNewswire
16 days ago
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
GlobeNewswire
a month ago
Palisade Bio to Participate in the Virtual Investor Closing Bell Series
GlobeNewswire
a month ago
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
GlobeNewswire
2 months ago
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108
GlobeNewswire
2 months ago
Palisade Bio to Present at the Virtual Investor Pitch Conference
GlobeNewswire
2 months ago
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
GlobeNewswire
2 months ago
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Compare PALI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PALI Palisade Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.